1 | list | 2,993 |
2 | margin | 1,636 |
3 | margins | 1,083 |
4 | deoxynucleotidyl | 125 |
5 | alkynes | 80 |
6 | filum | 25 |
7 | time-out | 20 |
8 | cisternae | 6 |
9 | deoxyribonucleotide | 6 |
10 | oxido | 6 |
11 | alpha-thalassaemia-1 | 5 |
12 | alpha-thalassemia-1 | 5 |
13 | list-controlled | 5 |
14 | stubs | 5 |
15 | deoxynucleotide | 4 |
16 | despeignes | 4 |
17 | krab | 4 |
18 | mini-tablet | 4 |
19 | polyacrylonitrile | 4 |
20 | sulcoflex | 4 |
21 | aldh2*1 | 3 |
22 | list-military | 3 |
23 | list/attention | 3 |
24 | list/treatment | 3 |
25 | method.the | 3 |
26 | methyldienoyl-coa | 3 |
27 | 1,3-diyne | 2 |
28 | 26-o-β-d-glucopyranoside | 2 |
29 | 5'-ta | 2 |
30 | deoxyribonucleotidyl | 2 |
31 | guide-line | 2 |
32 | intercrosses | 2 |
33 | list-control | 2 |
34 | mid-type | 2 |
35 | p.r631c | 2 |
36 | p.s113l | 2 |
37 | propenyl | 2 |
38 | pseudopodium | 2 |
39 | 'segmentectomy | 1 |
40 | 1-alkyl-2-oxo-2h-indol-1-ium | 1 |
41 | 2'-o-methylation | 1 |
42 | 33-a-c | 1 |
43 | 81.8-105.7 | 1 |
44 | alkene/alkyne | 1 |
45 | aphrodisias | 1 |
46 | arthropasty | 1 |
47 | autopolymerzing | 1 |
48 | babey | 1 |
49 | benzo-ring | 1 |
50 | boolchand | 1 |
51 | c.909 | 1 |
52 | cah-fetuses | 1 |
53 | co-regressors | 1 |
54 | cost-based-price | 1 |
55 | cyanoamidine | 1 |
56 | cytosine/cytosine/adenine | 1 |
57 | deoxylnucleotidyl | 1 |
58 | deoxynucleotidyl-transferase | 1 |
59 | deoxynucleotidyle | 1 |
60 | deoxynuleotidyl | 1 |
61 | diazafulvene | 1 |
62 | dose-relation | 1 |
63 | ductal-lobular | 1 |
64 | evaluated.overall | 1 |
65 | experience-matched | 1 |
66 | fcva-deposited | 1 |
67 | females=95.1±19.6 | 1 |
68 | grade/feedback | 1 |
69 | group.both | 1 |
70 | group:13 | 1 |
71 | group:22.35 | 1 |
72 | group:3/16 | 1 |
73 | group:7.76 | 1 |
74 | group:8/16 | 1 |
75 | half-phthalocyanine | 1 |
76 | healersâ | 1 |
77 | hydridomethyl | 1 |
78 | hyperbetalipoproteinaemia | 1 |
79 | insufficandy | 1 |
80 | invaginations.forty | 1 |
81 | j/kmol | 1 |
82 | long-postulated | 1 |
83 | m235 | 1 |
84 | metallacyclobutane | 1 |
85 | naocl-ch | 1 |
86 | nickelcentral | 1 |
87 | non-stimulus | 1 |
88 | oncomelanid | 1 |
89 | optimization™ | 1 |
90 | pads™ | 1 |
91 | period-related | 1 |
92 | phama | 1 |
93 | phase-that | 1 |
94 | phosphinidene-like | 1 |
95 | phosphorane | 1 |
96 | qualified-elaboration | 1 |
97 | recticularis | 1 |
98 | rectopexy.the | 1 |
99 | responsiveness/nonresponsiveness | 1 |
100 | si-f-al | 1 |
101 | siotf | 1 |
102 | sitoserolemia | 1 |
103 | steriled | 1 |
104 | sumtan | 1 |
105 | temperate-zone | 1 |
106 | thr307-asn680 | 1 |
107 | thr60met | 1 |
108 | time/cm | 1 |
109 | wild-mice | 1 |
110 | zucker/zdf | 1 |
1 | 'segmentectomy | 1 |
2 | 1,3-diyne | 2 |
3 | 1-alkyl-2-oxo-2h-indol-1-ium | 1 |
4 | 2'-o-methylation | 1 |
5 | 26-o-β-d-glucopyranoside | 2 |
6 | 33-a-c | 1 |
7 | 5'-ta | 2 |
8 | 81.8-105.7 | 1 |
9 | aldh2*1 | 3 |
10 | alkene/alkyne | 1 |
11 | alkynes | 80 |
12 | alpha-thalassaemia-1 | 5 |
13 | alpha-thalassemia-1 | 5 |
14 | aphrodisias | 1 |
15 | arthropasty | 1 |
16 | autopolymerzing | 1 |
17 | babey | 1 |
18 | benzo-ring | 1 |
19 | boolchand | 1 |
20 | c.909 | 1 |
21 | cah-fetuses | 1 |
22 | cisternae | 6 |
23 | co-regressors | 1 |
24 | cost-based-price | 1 |
25 | cyanoamidine | 1 |
26 | cytosine/cytosine/adenine | 1 |
27 | deoxylnucleotidyl | 1 |
28 | deoxynucleotide | 4 |
29 | deoxynucleotidyl | 125 |
30 | deoxynucleotidyl-transferase | 1 |
31 | deoxynucleotidyle | 1 |
32 | deoxynuleotidyl | 1 |
33 | deoxyribonucleotide | 6 |
34 | deoxyribonucleotidyl | 2 |
35 | despeignes | 4 |
36 | diazafulvene | 1 |
37 | dose-relation | 1 |
38 | ductal-lobular | 1 |
39 | evaluated.overall | 1 |
40 | experience-matched | 1 |
41 | fcva-deposited | 1 |
42 | females=95.1±19.6 | 1 |
43 | filum | 25 |
44 | grade/feedback | 1 |
45 | group.both | 1 |
46 | group:13 | 1 |
47 | group:22.35 | 1 |
48 | group:3/16 | 1 |
49 | group:7.76 | 1 |
50 | group:8/16 | 1 |
51 | guide-line | 2 |
52 | half-phthalocyanine | 1 |
53 | healersâ | 1 |
54 | hydridomethyl | 1 |
55 | hyperbetalipoproteinaemia | 1 |
56 | insufficandy | 1 |
57 | intercrosses | 2 |
58 | invaginations.forty | 1 |
59 | j/kmol | 1 |
60 | krab | 4 |
61 | list | 2,993 |
62 | list-control | 2 |
63 | list-controlled | 5 |
64 | list-military | 3 |
65 | list/attention | 3 |
66 | list/treatment | 3 |
67 | long-postulated | 1 |
68 | m235 | 1 |
69 | margin | 1,636 |
70 | margins | 1,083 |
71 | metallacyclobutane | 1 |
72 | method.the | 3 |
73 | methyldienoyl-coa | 3 |
74 | mid-type | 2 |
75 | mini-tablet | 4 |
76 | naocl-ch | 1 |
77 | nickelcentral | 1 |
78 | non-stimulus | 1 |
79 | oncomelanid | 1 |
80 | optimization™ | 1 |
81 | oxido | 6 |
82 | p.r631c | 2 |
83 | p.s113l | 2 |
84 | pads™ | 1 |
85 | period-related | 1 |
86 | phama | 1 |
87 | phase-that | 1 |
88 | phosphinidene-like | 1 |
89 | phosphorane | 1 |
90 | polyacrylonitrile | 4 |
91 | propenyl | 2 |
92 | pseudopodium | 2 |
93 | qualified-elaboration | 1 |
94 | recticularis | 1 |
95 | rectopexy.the | 1 |
96 | responsiveness/nonresponsiveness | 1 |
97 | si-f-al | 1 |
98 | siotf | 1 |
99 | sitoserolemia | 1 |
100 | steriled | 1 |
101 | stubs | 5 |
102 | sulcoflex | 4 |
103 | sumtan | 1 |
104 | temperate-zone | 1 |
105 | thr307-asn680 | 1 |
106 | thr60met | 1 |
107 | time-out | 20 |
108 | time/cm | 1 |
109 | wild-mice | 1 |
110 | zucker/zdf | 1 |
1 | thr307-asn680 | 1 |
2 | aldh2*1 | 3 |
3 | alpha-thalassaemia-1 | 5 |
4 | alpha-thalassemia-1 | 5 |
5 | group:13 | 1 |
6 | group:22.35 | 1 |
7 | m235 | 1 |
8 | females=95.1±19.6 | 1 |
9 | group:3/16 | 1 |
10 | group:8/16 | 1 |
11 | group:7.76 | 1 |
12 | 81.8-105.7 | 1 |
13 | c.909 | 1 |
14 | hyperbetalipoproteinaemia | 1 |
15 | sitoserolemia | 1 |
16 | phama | 1 |
17 | methyldienoyl-coa | 3 |
18 | 5'-ta | 2 |
19 | krab | 4 |
20 | 33-a-c | 1 |
21 | p.r631c | 2 |
22 | experience-matched | 1 |
23 | steriled | 1 |
24 | list-controlled | 5 |
25 | period-related | 1 |
26 | long-postulated | 1 |
27 | fcva-deposited | 1 |
28 | oncomelanid | 1 |
29 | boolchand | 1 |
30 | cisternae | 6 |
31 | wild-mice | 1 |
32 | cost-based-price | 1 |
33 | 26-o-β-d-glucopyranoside | 2 |
34 | deoxyribonucleotide | 6 |
35 | deoxynucleotide | 4 |
36 | method.the | 3 |
37 | rectopexy.the | 1 |
38 | phosphinidene-like | 1 |
39 | polyacrylonitrile | 4 |
40 | deoxynucleotidyle | 1 |
41 | phosphorane | 1 |
42 | metallacyclobutane | 1 |
43 | diazafulvene | 1 |
44 | cyanoamidine | 1 |
45 | guide-line | 2 |
46 | half-phthalocyanine | 1 |
47 | cytosine/cytosine/adenine | 1 |
48 | temperate-zone | 1 |
49 | 1,3-diyne | 2 |
50 | alkene/alkyne | 1 |
51 | mid-type | 2 |
52 | deoxynucleotidyl-transferase | 1 |
53 | zucker/zdf | 1 |
54 | siotf | 1 |
55 | benzo-ring | 1 |
56 | autopolymerzing | 1 |
57 | naocl-ch | 1 |
58 | group.both | 1 |
59 | grade/feedback | 1 |
60 | p.s113l | 2 |
61 | si-f-al | 1 |
62 | nickelcentral | 1 |
63 | evaluated.overall | 1 |
64 | j/kmol | 1 |
65 | list-control | 2 |
66 | deoxylnucleotidyl | 1 |
67 | deoxyribonucleotidyl | 2 |
68 | deoxynucleotidyl | 125 |
69 | deoxynuleotidyl | 1 |
70 | hydridomethyl | 1 |
71 | propenyl | 2 |
72 | time/cm | 1 |
73 | 1-alkyl-2-oxo-2h-indol-1-ium | 1 |
74 | pseudopodium | 2 |
75 | filum | 25 |
76 | sumtan | 1 |
77 | margin | 1,636 |
78 | dose-relation | 1 |
79 | 2'-o-methylation | 1 |
80 | qualified-elaboration | 1 |
81 | list/attention | 3 |
82 | oxido | 6 |
83 | ductal-lobular | 1 |
84 | aphrodisias | 1 |
85 | stubs | 5 |
86 | despeignes | 4 |
87 | alkynes | 80 |
88 | intercrosses | 2 |
89 | cah-fetuses | 1 |
90 | recticularis | 1 |
91 | margins | 1,083 |
92 | co-regressors | 1 |
93 | responsiveness/nonresponsiveness | 1 |
94 | non-stimulus | 1 |
95 | phase-that | 1 |
96 | mini-tablet | 4 |
97 | thr60met | 1 |
98 | list/treatment | 3 |
99 | list | 2,993 |
100 | time-out | 20 |
101 | sulcoflex | 4 |
102 | insufficandy | 1 |
103 | babey | 1 |
104 | 'segmentectomy | 1 |
105 | list-military | 3 |
106 | invaginations.forty | 1 |
107 | arthropasty | 1 |
108 | optimization™ | 1 |
109 | pads™ | 1 |
110 | healersâ | 1 |